

Pioneering Cellular Therapeutics to Reverse Aging and Eliminate Cancer

TREATING DISEASES OF AGING AND TREATING AGING AS DISEASE™

- Immorta Bio is revolutionizing **longevity cellular medicine**
- Our proprietary therapeutics **kill senescent (old) cells and introduce young cells**
- We leverage **patient-derived** rejuvenated stem cells and enhanced immune cells
- We restore the body's innate ability to **combat cancers and age-related diseases**

MARKET OPPORTUNITY

- **Rapid Growth:** Longevity and senolytics market projected to reach **\$46B** by 2033

KEYS TO SUCCESS

- **Proven Team** of biotech leaders and eminent scientists; 9 team members hold **MDs/PhDs**
- **Two Therapeutic Platforms**, AI enabled R&D, strong IP Portfolio: **23 patents**
- **Clinical Momentum:** Entering the clinical stage with **three IND's** to be cleared in 2025/2026
- **Clear Exit:** IPO **planned** in two years

ROAD TO IPO

- **Clinical Trials:** Complete Phase I/IIa longevity/lung cancer trial, launch two Phase I/IIa longevity/liver failure trials
- **R&D:** Advance longevity technologies and oncology franchise, expand IP, add peer-reviewed publications
- **Alliances:** Academic institutions, foundations and advanced biotech / pharma entities

OUR OVERALL OBJECTIVES

- **Mission-Oriented:** Achieve FDA approval for radical life extension therapeutics
- **Shareholder-Oriented:** Grow valuation to \$1B through advancing tech, IP, and clinical execution

PIPELINE

Technology	Product	Indication	Discovery	Preclinical Studies	FDA IND Enablement	Phase I/IIa
SenoVax™ Autologous Senolytic Immunotherapy	SNVL-31	Lung Cancer & Longevity PoC				
StemCell Revivify™ Personalized Progenitor Cells (PPC)	PPCH-01	Liver Failure & Longevity PoC				
StemCell Revivify™ Personalized Mesenchymal Stem Cells (PMSC)	PMSC-11	Liver Failure & Longevity PoC				
	PMSC-12	Sepsis				
SenoVax™ + StemCell Revivify™	LS-001	Systemic Longevity				

Reverse Aging - Prevent & Treat Cancer